Neogenomics Stock

Neogenomics Retained Earnings

The Retained Earnings of Neogenomics (NEO) as of Aug 16, 2026 is -433.81 M USD. In the previous year, Retained Earnings was -325.78 M USD — a change of 33.16% (lower).

Retained Earnings

-433.81 MUSD

YoY

33.16%

Last updated:

Retained Earnings of Neogenomics is 2026 -433.81 M USD. Retained Earnings of Neogenomics was 2025 -325.78 M USD. It decreases by 33.16% lower compared to the previous year.
Access this data via the Eulerpool API

Neogenomics Stock analysis

What does Neogenomics do? Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients. Neogenomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neogenomics stock

Retained Earnings of Neogenomics is -433.81 M USD in 2026.

Retained Earnings of Neogenomics changed from -325.78 M USD to -433.81 M USD, representing a 33.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Neogenomics since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Neogenomics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Neogenomics

All Key Metrics — Neogenomics